Cat:GMV-Crispr-LV008
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMV-Crispr-LV008 Categories , ,

Description

Cat No.

GMV-Crispr-LV008

Products Name

Type of Crispr

spCas9

Viral vector

spCas9

Promoter

CBH

Fluorescent/Resistance

mcherry

Tag

FLAG

Quantity/Unit

Vials

Form

Frozen form

Shipping and Storage Guidelines

Shipped by dry ice, stored at -80°C, effective for 1 year. Avoid repeatedly freezing and thawing.

Titer

> 1*10^8 TU/ml.

description

With Genemedi’s CRISPR/Cas9-gRNA lentivirus packaging service,scientists can easy to achieve multiple gene-knockout in different cell lines.Genemedi can also supply unique gene knockout service in specific cell line demanded with crispr/cas9 gene editing tool. HIV-1 (human immunodeficiency virus type I) based defective lentivirus has been one of the most widely used gene therapy vectors. It is a powerful tool for introduction of exogenous genes. The most advantageous feature of lentivirus vectors is to mediate efficient transfection and long-term expression of exogenous genes in both dividing and non-dividing cells. The lentivirus system has been widely used in various cell lines for gene overexpression, RNA interference, microRNA research and in vivo animal experiments. CRISPR/Cas9 gene editing technology has revolutionized the field of genome modification, using two key components that form a complex: Cas9 endonuclease and a single guide RNA (sgRNA) that guides Cas9 to a specific target site in the genomic DNA. It was listed as one of the top 10 breakthrough discovery in 2013. The technology has (1) higher targeting accuracy; (2) much more target sequence selection; (3) much less complexity; and (4) much less off-target cell toxicity than the previous genome editing technologies: TALEN (transcription activator-like effector nuclease) and ZEN (Zinc-finger nuclease). The Genemedi CRISPR/Cas9 System is a complete system for producing high yields of lentiviruses encoding the components necessary for CRISPR/Cas9-mediated genome editing [i.e., single guide RNA (sgRNA) and Cas9 nuclease] for delivery to mammalian cells that are difficult to transfect.

Advantages

1. High efficient Cas9 expression delivery with markers : High titer lentivirus providing more efficient Cas9 delivery in almost all cell 9 types including primary cells and non-dividing cells; Some Cas9 products include a fluorescent-antibiotic dual marker allowing the real-time check the lentivirus transduction efficiency. 2. Best nuclear penetrating for Cas9 enzyme: the Cas9 is expressed with an optimized, proprietary Nuclear Localization Signal (NLS), providing the efficient cas9 delivery into the nuclear region where the gene editing occur. 3. No need for tedious cloning work or vector construction: you can simply synthesize the gRNA (and donor cassette when desired) and used together with the Cas9 lentivirus for the gene editing. 4. Allow multiple gene editing at the same time: no need to construct each targeting vector for different gene. Instead, you just select the target sequence and synthesize the gRNA (each single strand RNA or double stranded DNA cassette) that to used with ourCas9 expression particles.

Quality control description

Our optimized custom lentiviral vector production and strict quality control systems provide customers a high titer of functional recombinant lentiviral vectors. Viral titers are determined by two methods: functional (infectious) titer (TU/mL) and physical titer (VP/mL). Physical titer is calculated by the level of protein, such as p24, or viral nucleic acid. The functional titer, a calculation of the active virus that can infect cells, is much less than the physical titer (100-1000 fold lower). Direct functional titer is an accurate solution for testing the MOI but is time consuming and not feasible. The physical titer is sufficient for most lentiviral experiments. Our main titration procedure is to determine the quantity of physical lentiviral particles. We can also calculate the functional lentiviral vectors with additional cost if required by customers.